Display options
Cite
Kawata S, Yashima K, Yamamoto S, et al. AID, p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa. Oncol Lett. 2015;10(2):737-743doi: 10.3892/ol.2015.3342.
Kawata, S., Yashima, K., Yamamoto, S., Sasaki, S., Takeda, Y., Hayashi, A., Matsumoto, K., Kawaguchi, K., Harada, K., & Murawaki, Y. (2015). AID, p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa. Oncology letters, 10(2), 737-743. https://doi.org/10.3892/ol.2015.3342
Kawata, Soichiro, et al. "AID, p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa." Oncology letters vol. 10,2 (2015): 737-743. doi: https://doi.org/10.3892/ol.2015.3342
Kawata S, Yashima K, Yamamoto S, Sasaki S, Takeda Y, Hayashi A, Matsumoto K, Kawaguchi K, Harada K, Murawaki Y. AID, p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa. Oncol Lett. 2015 Aug;10(2):737-743. doi: 10.3892/ol.2015.3342. Epub 2015 Jun 09. PMID: 26622562; PMCID: PMC4509115.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2015 Aug;10(2):737-743. doi: 10.3892/ol.2015.3342. Epub 2015 Jun 09.

AID, p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa.

Oncology letters

Soichiro Kawata, Kazuo Yashima, Sohei Yamamoto, Shuji Sasaki, Yohei Takeda, Akihiro Hayashi, Kazuya Matsumoto, Koichiro Kawaguchi, Kenichi Harada, Yoshikazu Murawaki

Affiliations

  1. Division of Medicine and Clinical Science, Faculty of Medicine, Tottori University, Nishicho, Yonago 683-8504, Japan.

PMID: 26622562 PMCID: PMC4509115 DOI: 10.3892/ol.2015.3342

Abstract

A number of tumor-associated genes have been associated with gastric cancer development. The present study evaluated differences in tumor-associated protein expression and phenotype among early gastric neoplasms, and correlated these data with those of the background mucosa. The expression of activation-induced cytidine deaminase (AID), p53 and MLH1 in 151 early gastric neoplasms [22 gastric adenomas, 92 intramucosal carcinomas (MCs), and 37 submucosal carcinomas (SMCs)] was examined immunohistochemically and compared with that of the corresponding background mucosal condition. The cellular phenotypes of the neoplasms and the corresponding background intestinal metaplasia were also determined. Aberrant AID, p53 and MLH1 expression was detected in 36.4, 0 and 0% of the adenomas, in 35.9, 32.6 and 16.3% of the MCs, and in 56.8, 62.2 and 21.6% of the SMCs, respectively. The frequency of aberrant AID and p53 expression in the SMCs was significantly increased compared with that in the MCs (AID, P<0.05; p53, P<0.01). Aberrant AID expression was significantly associated with p53 overexpression in the SMCs (P<0.01), but not in the adenomas or MCs. In addition, AID expression was associated with the severity of mononuclear cell activity in the non-cancerous mucosa adjacent to the tumor (P<0.05), particularly in the SMC cases. The percentage of MCs (34.8%) and SMCs (24.3%) that were of the gastric phenotype was higher compared with the percentage of adenomas (18.2%). These results indicated that p53 and MLH1 expression and a gastric phenotype may be important for carcinogenesis, and that chronic inflammation and AID and p53 expression are associated with submucosal progression.

Keywords: AID; endoscopic resection; gastric cancer; p53; phenotype

References

  1. Mutat Res. 2000 May 30;450(1-2):41-59 - PubMed
  2. Int J Cancer. 2008 Dec 15;123(12):2735-40 - PubMed
  3. World J Gastroenterol. 2006 Jun 28;12(24):3803-9 - PubMed
  4. World J Gastroenterol. 2006 Jan 14;12 (2):192-8 - PubMed
  5. Genes Dev. 2010 Oct 1;24(19):2107-14 - PubMed
  6. Int J Cancer. 2001 Oct 15;94(2):166-70 - PubMed
  7. Gut. 2000 Aug;47(2):251-5 - PubMed
  8. World J Gastrointest Oncol. 2012 Jun 15;4(6):131-7 - PubMed
  9. Oncogene. 2007 Aug 16;26(38):5587-95 - PubMed
  10. Br J Cancer. 2001 Oct 19;85(8):1147-52 - PubMed
  11. Gastroenterology. 2012 Sep;143(3):550-63 - PubMed
  12. Hepatology. 2008 Mar;47(3):888-96 - PubMed
  13. Br J Cancer. 2002 Aug 12;87(4):441-5 - PubMed
  14. Virchows Arch. 2011 Jun;458(6):717-24 - PubMed
  15. Nat Immunol. 2004 Nov;5(11):1166-74 - PubMed
  16. Acta Pathol Microbiol Scand. 1965;64:31-49 - PubMed
  17. Cancer Res. 1999 Mar 1;59(5):1090-5 - PubMed
  18. Oncology. 2002;62(2):175-9 - PubMed
  19. J Gastroenterol. 2014 Mar;49(3):427-35 - PubMed
  20. J Exp Med. 2003 May 5;197(9):1173-81 - PubMed
  21. Am J Surg Pathol. 1996 Oct;20(10):1161-81 - PubMed
  22. Int J Cancer. 2010 Dec 1;127(11):2500-9 - PubMed
  23. J Korean Med Sci. 2005 Apr;20(2):236-41 - PubMed
  24. Oncology. 2001;61(3):212-20 - PubMed
  25. Pathol Int. 1999 Jan;49(1):55-61 - PubMed
  26. Gan. 1968 Jun;59(3):251-8 - PubMed
  27. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  28. Cancer Res. 1992 Dec 15;52(24):6735-40 - PubMed
  29. Eur J Gastroenterol Hepatol. 1994 Dec;6 Suppl 1:S79-83 - PubMed
  30. Cancer. 2000 Aug 15;89(4):724-32 - PubMed
  31. Tumour Biol. 2007;28(6):333-9 - PubMed
  32. N Engl J Med. 2001 Sep 13;345(11):784-9 - PubMed
  33. Oncogene. 2002 Oct 21;21(48):7435-51 - PubMed
  34. Cell. 2000 Sep 1;102(5):553-63 - PubMed
  35. J Histochem Cytochem. 2005 Jan;53(1):75-85 - PubMed
  36. Gastroenterology. 2008 Sep;135(3):889-98, 898.e1-3 - PubMed
  37. Nat Med. 2007 Apr;13(4):470-6 - PubMed
  38. Oncogene. 2013 Jul 25;32(30):3531-42 - PubMed

Publication Types